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Background: Asthma is a chronic airway inflammatory disease. Measurement of serum high-
sensitivity C-reactive protein (hs-CRP) levels has suggested the involvement of low-grade
systemic inflammation in several disorders, such as cardiovascular disease and diabetes melli-
tus. In recent years, there have been some reports concerning hs-CRP assessment as a useful
tool for detecting systemic inflammation in asthma. The study was undertaken to evaluate hs-
CRP levels in the exhaled breath condensate (EBC) of asthmatics with different degrees of
asthma severity and their relationship to hs-CRP levels in serum, clinical characteristics, and
the intensification of airway inflammation.
Methods: The study group was 62 patients with allergic asthma (20 with steroid-naı¨ve mild
asthma, 19 with ICS-treated, stable mild-to-moderate asthma, 23 with ICS-treated unstable,
severe asthma) and 15 healthy volunteers.
Results: In the three groups of asthmatics hs-CRP concentrations in EBC and serum were signif-
icantly higher than in healthy volunteers. hs-CRP levels both in EBC and serum were signifi-
cantly higher in patients with unstable asthma than in the two groups with stable disease.
hs-CRP concentrations in EBC strongly correlated with those measured in serum. There was
a significant correlation between hs-CRP levels both in EBC and serum and exhaled nitric oxide
(FENO) in the three groups of asthmatics or serum ECP in the group of patients with steroid-
naı¨ve mild asthma and unstable, severe asthma.746 8373; fax: þ48 85 746 8601.
l (Z. Zietkowski).
8 Elsevier Ltd. All rights reserved.
380 Z. Zietkowski et al.Conclusion: The levels of hs-CRP in EBC are correlated with those measured in serum and may
provide another useful diagnostic tool for detecting and monitoring low-grade inflammation in
patients with asthma.
ª 2008 Elsevier Ltd. All rights reserved.Introduction
Asthma is characterized by airway hyper-responsiveness
and chronic inflammation in which various cells, cytokines
and mediators play a role.1 It has been shown that levels of
acute phase proteins (such as plasma fibrinogen and serum
amyloid A) are positively associated with the prevalence of
asthma.2 It has also been demonstrated that increased
levels of amyloid A are present in patients with asymp-
tomatic asthma.3 Therefore, it is very likely that systemic
inflammation may exist in asthma.
C-reactive protein is synthesized mainly by hepatocytes
and BrowiczeKupffer cells. Monocytes and lymphocytes are
also able to produce CRP.4,5 The mechanisms of activation
of CRP synthesis are still not fully understood. It has been
shown that the main stimulators of this process are IL-1, IL-
6 and TNFa cytokines with a recognized important role in
the pathophysiology of asthma. IL-6 has growth-regulatory
effects on many cells and is involved in T-cell activation,
growth, and differentiation. It also activates the gene
responsible for CRP synthesis through phosphorylation of
the transcription factor.5,6
In man, CRP has many important functions, but some of
them are still unknown. The main biological role of CRP is
the ability to recognize bacteria and damaged human cells
and to mediate their elimination through complement and
activation of phagocytic cells. CRP is present in the serum
of healthy persons; an intensification in CRP synthesis and
secretion can be observed in inflammatory processes and
malignancies.7,8
CRP is one of the most characteristic markers of the
inflammatory process. The monitoring of CRP levels is
a good diagnostic tool and is very useful in the assessment
of early inflammation, as well as in treatment monitoring
and efficacy in acute-phase diseases.9 The use of high-
sensitivity assays for CRP determination (hs-CRP) has made
the assessment of low-grade systemic inflammation
possible in several disorders, such as cardiovascular disease
and diabetes mellitus.10,11
In recent years, there have been some reports con-
cerning the measurement of serum levels of hs-CRP as
a useful tool for detecting systemic inflammation in
asthma.12,13 There were few studies about using exhaled
breath condensate (EBC) for the assessment of hs-CRP
levels in asthma patients. EBC, collected by cooling exhaled
air, is a non-invasive, easily performed, rapid, and effort-
independent method for obtaining samples from the lower
respiratory tract. There has been increasing interest in
measuring EBC in the assessment of inflammatory
biomarkers (both local and systemic) in the pathophysi-
ology and treatment monitoring of asthma.14
The aim of the study was to assess hs-CRP levels in
the EBC of asthmatics with different degrees of disease
severity, and to establish the possible correlation ofthese measurements with hs-CRP serum levels and with
other parameters commonly associated with airway
inflammation.
Methods
Study population and design
The study was conducted on three groups: 20 steroid-naı¨ve
mild allergic asthma patients, 19 patients treated with
inhaled corticosteroids (ICS) with stable mild-to-moderate
allergic asthma, and 23 ICS-treated patients with severe,
unstable allergic asthma. Asthma was diagnosed according
to the criteria recommended by the GINA 2006.15 None of
the patients with asthma had complications of other lung
diseases or a history suggesting systemic infection,
tumours, or autoimmune diseases. Patients with sinus
disease were excluded by means of interview. Subjects
with heart disease, diabetes mellitus, cancer status,
obesity (body mass index BMI >30 kg/m2) and systemic
inflammatory disorders (such as collagen vascular diseases)
were excluded from the study.
The steroid-naı¨ve asthmatics have not been treated with
ICS and were free from acute exacerbations and respiratory
tract infections during the 3 months prior to the study.
Patients with stable, mild-to-moderate asthma had been
treated with low- to- medium doses of ICS at a constant
dose for at least 3 months. Stable asthma was defined as
a minimal need for rescue medications (short-acting b2-
agonists), no exacerbations, and no use of systemic steroids
in the previous 12 months. The patients with severe,
unstable asthma had required one or more hospitalizations
for asthma and more than three oral steroid bursts in the
last year. They had been taking high-doses of ICS and long-
acting b2-agonists for at least 6 months. Patients who had
respiratory tract infections in the last month before the
study were excluded from this study. All the patients were
atopic and sensitized to common inhaled allergens, as
evaluated by skin prick tests.
Fifteen healthy volunteers were used as a negative
control group. They were free of respiratory tract infection
within 3 months prior to the study, and from either other
significant illnesses known to affect exhaled nitric oxide
(FENO) measurements or hs-CRP levels (which have been
described previously). Asthma patients and healthy volun-
teers were non-smokers and during the last year have not
been passive smokers.
All of the patients and healthy volunteers were exam-
ined by a physician, then underwent EBC collection, FENO
measurement, and spirometry. Blood samples were
collected to determine serum hs-CRP, ECP, total IgE and
blood eosinophil count.
The study protocol was approved by the Ethics of
Research Committee of the Medical University of Bialystok,
Serum hs-CRP levels in EBC of asthmatics 381number of agreement: R-I-003/80/2006. Informed consent
was obtained from every patient entered into the study.
Measurements
Exhaled nitric oxide (FENO) was measured by the chem-
iluminescence technique using a Sievers 280i NO Analyzer
(Boulder, CO, USA). The measurements were performed at
an expiratory flow of 50 ml/s according to ATS recommen-
dations for on-line measurement of FENO in adults.
16
The spirometry (FEV1) was performed using a Master-
Screen Pneumo PC spirometer (Jaeger, Hoechberg,
Germany), according to ATS standards.17
EBC was collected by using a commercially available
condenser (EcoScreen; Erich Jaeger GmbH, Hoechberg,
Germany) according to current ATS/ERS guidelines.14 All
measurements were performed at the same time (between
08:00 and 10:00 h ) to avoid possible circadian rhythm of
mediator concentrations in EBC. All patients were asked to
refrain from eating and drinking before EBC collection.
Exhaled air entered and left the chamber through one-way
valves and an inlet and outlet, thus keeping the chamber
closed. Low temperature inside the condensing chamber
throughout the collection time produced a cooling down
sample. The temperature of collection was around 0 C.14,18
Patients were instructed to breathe tidally for 10 min with
a nose clip. The respiratory rate ranged from 15 to 20 breaths
perminute. At the end of collection 1.5- to 3.5-ml aliquots of
condensate were transferred to Eppendorf tubes and
immediately frozen. Samples were stored at 80 C.19
Serum total IgE concentrations and serum ECP were
measured using ImmunoCAP Technology (Pharmacia
Diagnostics, Uppsala, Sweden). The minimum detectable
level of ECP was 2.0 mg/l. Blood eosinophil count was
measured using a haematologic analyzer (Coulter Elec-
tronics GmbH, Miami, FL, USA). The concentrations of hs-
CRP in EBC and serum were determined using a highly
sensitive CRP assay (Konelab, Waltham, MA, USA). TheTable 1 Characteristics of study subjects and healthy voluntee
Characteristics Dimension Healthy
volunteers
No. of patients 15
Sex F/M 9/6
Age years 33.136.71
Duration of symptoms years
Baseline FEV1 % pred 101.468.77c
Serum total IgE concentration kU/l 57.824.7a,b,c
Blood eosinophil count cells/mm3 5319a,b,c
BMI kg/m2 21.03.2
FENO ppb 15.464.61a,b,c
ECP (serum) mg/l 3.130.73a,b,c
ICS, inhaled corticosteroid; FEV1, forced expiratory volume in on
EBC, exhaled breath condensate; ECP, eosinophil cationic protein.
Data are presented as medians (ranges).
a Values significantly different from patients with stable, steroid-na
b Values significantly different from patients with stable, ICS-treate
c Values significantly different from patients with unstable asthma,method is based on the measurement of immunoprecipi-
tation at 540 nm. Microparticles coated with anti-human
CRP are added to buffered samples. The increase in
absorbance caused by immunoprecipitation is recorded
when the reaction has reached its end-point. The change in
absorbance is proportional to the amount of antigen (CRP)
in the solution. The minimum detectable level of hs-CRP
was 0.05 mg/l.
Statistical analysis
Statistical significance was analysed by using analysis of
variance (ANOVA) followed by Bonferroni’s t-test post hoc
to determine statistical differences. All values were
expressed as mean  SD; p values of <0.05 were considered
significant. The relationship between studied parameters
was assayed by correlation. Pearson’s linear correlation
coefficient was used.
Results
Characteristics of asthmatic patients and healthy volun-
teers are presented in Table 1.
In the three groups of asthmatics, EBC levels of hs-CRP
were significantly higher than those detected in healthy
volunteers (steroid-naı¨ve stable asthma: 0.170.05 mg/l,
p < 0.0001; ICS-treated stable asthma: 0.160.06, p <
0.0001; unstable asthma: 0.290.04, p < 0.0001; healthy
volunteers: 0.080.03) (Fig. 1). hs-CRP levels in EBC were
significantly elevated in patients with unstable asthma
compared with ICS-treated stable asthma patients
(p < 0.0001) and steroid-naı¨ve asthmapatients (p < 0.0001).
Serum levels of hs-CRP in all groups of asthmatics were
significantly higher than those measured in healthy volun-
teers (steroid-naı¨ve stable asthma: 1.360.54 mg/l, p <
0.0001; ICS-treated stable asthma: 1.070.28, p < 0.0001;
unstable asthma: 2.691.04, p < 0.0001; healthy volun-
















e second; BMI, body mass index; FENO, exhaled nitric oxide;
ı¨ve asthma, p < 0.05.
d asthma, p < 0.05.
p < 0.05.
Figure 1 Concentrations of hs-CRP in EBC in studied groups
of asthma patients and healthy volunteers.
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compared with ICS-treated stable asthma patients
(p < 0.0001) and steroid-naı¨ve asthma patients (p < 0.001).
There were no significant differences in EBC (pZ 0.98)
and serum (pZ 0.59) levels of hs-CRP between stable ICS-
treated and steroid-naı¨ve asthma patients.
A statistically significant correlation between hs-CRP
levels in serum and EBC in all studied groups of asthmatics
was revealed. Such a correlation was not observed in
healthy volunteers (Fig. 3).
We revealed statistically significant positive correlations
between levels of hs-CRP in EBC or serum and FENO in the
three studied groups of asthmatics. We discovered a signif-
icantly positive correlation between hs-CRP in EBC or serum
and serum ECP in the group of asthmatics with severe,
unstable asthma and steroid-naı¨ve, stable asthma patients.
A significantly positive correlation between hs-CRP in serum
and blood eosinophil count in the group of steroid-naı¨ve,
stable asthma patients was also revealed. There was no
statistically significant correlation between hs-CRP in EBC
or serum and other studied parameters in any of the studied
groups of asthmatics and healthy volunteers. The results
are presented in Tables 2 and 3.
Discussion
C-reactive protein is one of the most characteristic markers
of the inflammatory process. There are some reportsFigure 2 Concentrations of hs-CRP in serum in studied
groups of asthma patients and healthy volunteers.concerning the possibility of using hs-CRP measurements to
assess subclinical, systemic inflammation in asthma.
However, studies in which no high- sensitivity methods of
CRP measurements were used have not revealed any
difference in CRP levels between controls and asthmatic
patients.3 On the other hand, a population-based study has
shown associations of increased levels of serum hs-CRP with
a high frequency of airway hyper-responsiveness and low
forced expiratory volume in 1 s (FEV1), and these results
may suggest that systemic inflammation can be associated
with respiratory impairment.20
Olafsdottir et al. have demonstrated that raised serum
levels of hs-CRP are associated with respiratory symptoms
in asthmatic patients.21 The authors also reveal that an
increase in serum hs-CRP levels correlated with the degree
of airway obstruction. Moreover, they suggest that serum
hs-CRP levels may be related to the state of asthma control
and chronic airway inflammation and hs-CRP measurements
could be useful in the management of asthmatic patients.21
Takemura et al. have found that, in patients with
steroid-naı¨ve asthma, serum levels of hs-CRP were
increased compared with healthy volunteers, and corre-
lated negatively with indices of pulmonary function and
positively with numbers of sputum eosinophils.12
Fujita et al. suggest that serum hs-CRP levels may be
a marker of atopic and non-atopic asthma. These authors
demonstrate a significant correlation between serum hs-
CRP and ECP levels and they suppose that increased hs-CRP
levels may be associated with allergic, particularly eosin-
ophilic, inflammation.13
Several factors might affect serum levels of hs-CRP. The
presence of cardiovascular disease, diabetes mellitus or
obesity is associated with increased serum hs-CRP levels,
which may be due to adipocyte-derived interleukin-6.10,22
Smokers also show elevated levels of hs-CRP and smoking
cessation leads to their reduction.23 Ageing is another
factor of elevated hs-CRP levels.24 In our study, patients
and healthy volunteers were carefully selected to exclude
these confounding factors.
Our results confirmed the presence of low-grade
systemic inflammation in asthma as shown previ-
ously.2,3,12,13 We performed the measurement of hs -CRP
both in serum and EBC. In previous studies, Rosias et al.
were not able to demonstrate the presence of CRP in the
EBC of asthmatic children and healthy controls.25 However,
the authors emphasized that high-sensitivity assays for
measurement of inflammatory markers in EBC should be
used. In the study performed by Ueno et al., in which CRP
was measured using ELISA with a high sensitivity, the
authors revealed raised CRP levels in the EBC in asthmatics
compared with healthy volunteers. However, in this study
the correlations between CRP concentrations in EBC and
asthma severity or other markers of airway inflammation
were not observed.26
Our study shows that hs-CRP levels in EBC and serum are
higher in asthmatic patients than in healthy controls. In
patients with unstable asthma, levels of hs-CRP were
significantly higher than in steroid-naı¨ve and ICS-treated
patients with stable asthma. This observation was
confirmed by the previous studies performed by Qian et al.,
in which the highest serum CRP levels in patients with
severe persistent asthma were demonstrated.27 We
Figure 3 Correlations between hs-CRP levels in serum and exhaled breath condensate in studied groups of asthma patients and
healthy volunteers.
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in EBC and serum, as well as between the results of these
measurements and other inflammatory markers (such as
FENO and ECP).
Reports from the EBC Task Force by the major American
and European respiratory societies state that although
dilution may be a factor influencing EBC data, it does not
appear to improve reproducibility.14 Because the marker
used to correct the difference in the degree of dilution has
not yet been established, in our study we have not made
any attempt to assess the dilution of airway lining fluid in
EBC. One of the main reasons for the difference between
EBC and serum level of CRP can be dilution of EBC.
However, analysis of study results and significant correla-
tion between serum and EBC levels of CRP suggest that
differences in mediator levels observed in various degrees
of asthma severity can not be explained by the dilution
effect of EBC.Table 2 Correlations between the levels of hs-CRP in serum an
and healthy volunteers.
Studied groups FENO Serum ECP
Healthy volunteers rZ 0.41 rZ 0.48
pZ 0.12 pZ 0.07
Stable asthma steroid-naı¨ve rZ 0.52 rZ 0.69
pZ 0.01 pZ 0.0006
Stable asthma ICS-treated rZ 0.62 rZ 0.31
pZ 0.004 pZ 0.18
Unstable asthma rZ 0.71 rZ 0.68
pZ 0.0001 pZ 0.0003We observed significantly increased levels of hs-CRP in
EBC in asthmatic patients compared to healthy volunteers
but the difference were not proportional to those observed
in serum. In our opinion presence of inflammatory process
in asthmatic patients can lead to a change in EBC mediator
concentration. Allergic inflammation, increase of vascular
permeability but on the other hand thickening and swelling
of airway mucus, overproduction of mucus, and forced
respiration can also influence EBC composition. In stable,
mild- to- moderate asthmatic patients treated with ICS,
EBC and serum hs-CRP levels did not significantly differ
from those of steroid- naı¨ve mild asthma and did not
correlate with serum ECP concentrations. This could
suggest the beneficial effect of ICS treatment in down-
regulation of CRP. This suggestion is confirmed by
a previous study performed by Takemura et al., in which hs-
CRP levels in serum were measured.12 However, more
studies are needed to assess the influence of ICS on hs-CRPd other studied parameters in the groups of asthma patients
Blood eosinophil count Serum total IgE Baseline FEV1
rZ 0.24 rZ 0.02 rZ 0.14
pZ 0.38 pZ 0.93 pZ 0.60
rZ 0.50 rZ 0.36 rZ 0.22
pZ 0.02 pZ 0.11 pZ 0.34
rZ 0.40 rZ 0.41 rZ 0.11
pZ 0.09 pZ 0.07 pZ 0.64
rZ 0.17 rZ 0.21 rZ 0.41
pZ 0.42 pZ 0.32 pZ 0.15
Table 3 Correlations between the levels of hs-CRP in EBC and other studied parameters in the groups of asthma patients and
healthy volunteers.
Studied groups FENO Serum ECP Blood eosinophil count Serum total IgE Baseline FEV1
Healthy volunteers rZ 0.47 rZ 0.49 rZ 0.16 rZ 0.33 rZ 0.28
pZ 0.08 pZ 0.10 pZ 0.54 pZ 0.21 pZ 0.29
Stable asthma steroid-naı¨ve rZ 0.79 rZ 0.84 rZ 0.31 rZ 0.17 rZ 0.04
pZ 0.00002 pZ 0.00003 pZ 0.17 pZ 0.44 pZ 0.85
Stable asthma ICS-treated rZ 0.58 rZ 0.32 rZ 0.40 rZ 0.16 rZ 0.07
pZ 0.008 pZ 0.16 pZ 0.08 pZ 0.50 pZ 0.76
Unstable asthma rZ 0.67 rZ 0.57 rZ 0.22 rZ 0.20 rZ 0.18
pZ 0.0003 pZ 0.004 pZ 0.30 pZ 0.34 pZ 0.39
384 Z. Zietkowski et al.levels in EBC and serum, as well as the usefulness of hs-CRP
measurements in monitoring anti-inflammatory treatment.
In recent studies concerning hs-CRP assessment in
asthma, the authors have focused on the possibility of using
hs-CRP measurements as a marker of low-grade systemic
inflammation in asthma. It is worth noting that CRP could
also serve as a mediator of inflammation. CRP could elicit
macrophage activation (through interaction with Fc
receptors for antibodies).28 CRP inhibits T- lymphocyte
binding to antigen receptors (TCR). It has been demon-
strated that CRP acts directly on monocytes and neutrophils
through recognizing CRP-R receptors on their surface.6 The
population of monocytes with specific surface antigen
determinants with an affinity to CRP has also been
described.29
CRP action in vivo is a result of CRP interactions with
blood cells (through receptor-binding or extra-receptor
action) and/or serum ingredients. Direct CRP interaction
with cells is mediated by at least three Fcg receptors.
FcgRIIa (CD32) receptor and FcgRIIIb (CD16) receptor are
regarded as low-affinity CRP receptors, in contrast to the
high-affinity CRP receptor FcgRI (CD64).29,30 FcgRI and
FcgRIIa are regarded as the main receptors participating in
the interaction between leukocytes or endothelial cells
with CRP during inflammation.31 It has been shown that CRP
could interact with blood platelets through phosphocholine
(present in cell membrane phospholipids), through PAF
receptors as well as through FcgRIIa receptors (responsible
for plateleteleukocyte interaction).32 CRP induces cytokine
production such as monocyte chemoattractant protein-1
(MCP-1), and expression of adhesion molecules in endo-
thelial cells.33
In recent years, the use of EBC as a non-invasive method
for the assessment of samples from the airways has become
more and more popular. The analysis of EBC allows for the
measurement of mediators of local inflammation, synthe-
sized in airways, as well as for the assessment of systemic
inflammation through the evaluation of mediators trans-
ported with blood.
Based on this information, the possibility of hs-CRP
assessment as a marker of low-grade systemic inflammation
in samples taken from the airways of asthmatics seems to
be very attractive. The measurement of hs-CRP in EBC of
asthma patients may be another useful diagnostic tool for
detecting and monitoring inflammation, disease severity,
and response to treatment. However, future studies areneeded for better assessment of the clinical significance of
hs- CRP measurements, both in EBC and serum, in diag-
nostics and in treatment of asthmatic patients.
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